These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 36701817)

  • 21. Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2022 Jun; 18(6):381-393. PubMed ID: 35876091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis.
    Younes AM; Salem M; Maraey A; Nomigolzar S; Sewell K; Khalil M; Elzanaty A; Saeyeldin A; Dar M
    Int J Cardiol; 2022 Nov; 366():51-56. PubMed ID: 35777490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
    Starr JA; Pinner NA; Lisenby KM; Osmonson A
    Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
    O'Meara E; Verma S
    Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
    Jhund PS
    Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
    Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM
    J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
    Savarese G; Butler J; Lund LH; Bhatt DL; Anker SD
    Cardiovasc Res; 2022 Jul; 118(10):2231-2252. PubMed ID: 34390570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
    Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
    Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses.
    March KL; Lukas JG; Berei TJ; Shah SP; Cave BE
    Crit Care Nurs Q; 2022 Apr-Jun 01; 45(2):189-198. PubMed ID: 35212658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection.
    Rastogi T; Girerd N
    Heart Fail Clin; 2022 Oct; 18(4):561-577. PubMed ID: 36216486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
    Liu Z; Ma X; Ilyas I; Zheng X; Luo S; Little PJ; Kamato D; Sahebkar A; Wu W; Weng J; Xu S
    Theranostics; 2021; 11(9):4502-4515. PubMed ID: 33754074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021.
    Gonzalez J; Dave CV
    BMC Cardiovasc Disord; 2024 May; 24(1):285. PubMed ID: 38816795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
    Al Rifai M; Newby LK; Nair AP; Misra A; Rogers JG; Fedson S; Virani SS
    Curr Atheroscler Rep; 2022 Aug; 24(8):627-634. PubMed ID: 35653033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis.
    Fukuta H; Hagiwara H; Kamiya T
    Medicine (Baltimore); 2021 Dec; 100(51):e28448. PubMed ID: 34941199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 37. Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction.
    Elserafy AS; Reda A; Farag E; Mostafa T; Farag N; Elbahry A; Sanad O; Bendary A; Elkersh A; Attia I; Selim M; Khamis H; Issak ER
    Clin Drug Investig; 2021 Dec; 41(12):1027-1036. PubMed ID: 34780022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
    Täger T; Frankenstein L; Atar D; Agewall S; Frey N; Grundtvig M; Clark AL; Cleland JGF; Fröhlich H
    Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction?
    Wu YJ; Wang SB; Wang LS
    Am J Cardiovasc Drugs; 2022 Nov; 22(6):601-613. PubMed ID: 35947249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction.
    Monzo L; Ferrari I; Cicogna F; Tota C; Calò L
    Int J Cardiol; 2021 Oct; 341():56-59. PubMed ID: 34454968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.